TipRanks
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
US Market
IOVA
Iovance Biotherapeutics
RESEARCH TOOLSreports
Want to see IOVA full AI Analyst Report?

Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

4,291 Followers
See the Price Targets and Ratings of:

IOVA Analyst Ratings

Strong Buy
10Ratings
Strong Buy
8 Buy
2 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Iovance
Biotherapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IOVA Stock 12 Month Forecast

Average Price Target

$14.40
▲(70.62% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Iovance Biotherapeutics in the last 3 months. The average price target is $14.40 with a high forecast of $20.00 and a low forecast of $7.00. The average price target represents a 70.62% change from the last price of $8.44.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","21":"$21","5.25":"$5.25","10.5":"$10.5","15.75":"$15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.25,10.5,15.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.23,14.673846153846155,15.117692307692309,15.561538461538461,16.005384615384617,16.44923076923077,16.893076923076922,17.336923076923078,17.78076923076923,18.224615384615383,18.66846153846154,19.11230769230769,19.556153846153848,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.23,14.243076923076924,14.256153846153847,14.26923076923077,14.282307692307693,14.295384615384616,14.30846153846154,14.321538461538461,14.334615384615384,14.347692307692308,14.36076923076923,14.373846153846154,14.386923076923077,{"y":14.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.23,13.673846153846155,13.117692307692309,12.561538461538461,12.005384615384616,11.44923076923077,10.893076923076922,10.336923076923076,9.78076923076923,9.224615384615385,8.668461538461539,8.112307692307692,7.556153846153846,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.73,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.97,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.07,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.28,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.23,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$20.00Average Price Target$14.40Lowest Price Target$7.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on IOVA
Etzer Darout
Barclays
Barclays
$15→$18
Buy
113.27%
Upside
Reiterated
10/13/26
Iovance Biotherapeutics (IOVA) Receives a Buy from Barclays
Jefferies Analyst forecast on IOVA
Andrew Tsai
Jefferies
Jefferies
$20
Buy
136.97%
Upside
Reiterated
10/12/26
Jefferies Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)
Robert W. Baird Analyst forecast on IOVA
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
$6→$11
Hold
30.33%
Upside
Reiterated
10/08/26
Iovance Biotherapeutics price target raised to $11 from $6 at BairdIovance Biotherapeutics price target raised to $11 from $6 at Baird
H.C. Wainwright Analyst forecast on IOVA
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$20
Buy
136.97%
Upside
Assigned
09/30/26
Iovance Biotherapeutics price target raised to $20 from $9 at H.C. WainwrightIovance Biotherapeutics price target raised to $20 from $9 at H.C. Wainwright
Wells Fargo Analyst forecast on IOVA
Yanan Zhu
Wells Fargo
Wells Fargo
$14→$18
Buy
113.27%
Upside
Assigned
09/30/26
Iovance Biotherapeutics price target raised to $18 from $14 at Wells FargoIovance Biotherapeutics price target raised to $18 from $14 at Wells Fargo
TD Cowen Analyst forecast on IOVA
Nicholas Lorusso
TD Cowen
TD Cowen
$10→$16
Buy
89.57%
Upside
Reiterated
09/29/26
Iovance Biotherapeutics (IOVA) Receives a Buy from TD Cowen
Goldman Sachs Analyst forecast on IOVA
Andrea Newkirk
Goldman Sachs
Goldman Sachs
$15
Buy
77.73%
Upside
Initiated
09/24/26
Analysts Offer Insights on Healthcare Companies: Palisade Bio (NASDAQ: PALI) and Iovance Biotherapeutics (NASDAQ: IOVA)
UBS Analyst forecast on IOVA
David Dai
UBS
UBS
$4→$7
Hold
-17.06%
Downside
Assigned
08/20/26
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), CervoMed (NASDAQ: CRVO) and Korro Bio (NASDAQ: KRRO)
Mizuho Securities Analyst forecast on IOVA
Salim Syed
Mizuho Securities
Mizuho Securities
$10→$11
Buy
30.33%
Upside
Reiterated
08/17/26
Mizuho Securities Remains a Buy on Iovance Biotherapeutics (IOVA)
Citizens JMP Analyst forecast on IOVA
Reni Benjamin
Citizens JMP
Citizens JMP
$5→$8
Buy
-5.21%
Downside
Reiterated
08/07/26
Iovance Biotherapeutics price target raised to $8 from $5 at CitizensIovance Biotherapeutics price target raised to $8 from $5 at Citizens
Chardan Capital Analyst forecast on IOVA
Geulah Livshits
Chardan Capital
Chardan Capital
$14
Buy
65.88%
Upside
Reiterated
05/07/26
Iovance Biotherapeutics price target lowered to $14 from $16 at ChardanIovance Biotherapeutics price target lowered to $14 from $16 at Chardan
Leerink Partners Analyst forecast on IOVA
Asthika Goonewardene
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
02/25/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (NASDAQ: IOVA), Erasca (NASDAQ: ERAS) and Tempus AI, Inc. Class A (NASDAQ: TEM)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on IOVA
Etzer Darout
Barclays
Barclays
$15→$18
Buy
113.27%
Upside
Reiterated
10/13/26
Iovance Biotherapeutics (IOVA) Receives a Buy from Barclays
Jefferies Analyst forecast on IOVA
Andrew Tsai
Jefferies
Jefferies
$20
Buy
136.97%
Upside
Reiterated
10/12/26
Jefferies Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)
Robert W. Baird Analyst forecast on IOVA
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
$6→$11
Hold
30.33%
Upside
Reiterated
10/08/26
Iovance Biotherapeutics price target raised to $11 from $6 at BairdIovance Biotherapeutics price target raised to $11 from $6 at Baird
H.C. Wainwright Analyst forecast on IOVA
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$20
Buy
136.97%
Upside
Assigned
09/30/26
Iovance Biotherapeutics price target raised to $20 from $9 at H.C. WainwrightIovance Biotherapeutics price target raised to $20 from $9 at H.C. Wainwright
Wells Fargo Analyst forecast on IOVA
Yanan Zhu
Wells Fargo
Wells Fargo
$14→$18
Buy
113.27%
Upside
Assigned
09/30/26
Iovance Biotherapeutics price target raised to $18 from $14 at Wells FargoIovance Biotherapeutics price target raised to $18 from $14 at Wells Fargo
TD Cowen Analyst forecast on IOVA
Nicholas Lorusso
TD Cowen
TD Cowen
$10→$16
Buy
89.57%
Upside
Reiterated
09/29/26
Iovance Biotherapeutics (IOVA) Receives a Buy from TD Cowen
Goldman Sachs Analyst forecast on IOVA
Andrea Newkirk
Goldman Sachs
Goldman Sachs
$15
Buy
77.73%
Upside
Initiated
09/24/26
Analysts Offer Insights on Healthcare Companies: Palisade Bio (NASDAQ: PALI) and Iovance Biotherapeutics (NASDAQ: IOVA)
UBS Analyst forecast on IOVA
David Dai
UBS
UBS
$4→$7
Hold
-17.06%
Downside
Assigned
08/20/26
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), CervoMed (NASDAQ: CRVO) and Korro Bio (NASDAQ: KRRO)
Mizuho Securities Analyst forecast on IOVA
Salim Syed
Mizuho Securities
Mizuho Securities
$10→$11
Buy
30.33%
Upside
Reiterated
08/17/26
Mizuho Securities Remains a Buy on Iovance Biotherapeutics (IOVA)
Citizens JMP Analyst forecast on IOVA
Reni Benjamin
Citizens JMP
Citizens JMP
$5→$8
Buy
-5.21%
Downside
Reiterated
08/07/26
Iovance Biotherapeutics price target raised to $8 from $5 at CitizensIovance Biotherapeutics price target raised to $8 from $5 at Citizens
Chardan Capital Analyst forecast on IOVA
Geulah Livshits
Chardan Capital
Chardan Capital
$14
Buy
65.88%
Upside
Reiterated
05/07/26
Iovance Biotherapeutics price target lowered to $14 from $16 at ChardanIovance Biotherapeutics price target lowered to $14 from $16 at Chardan
Leerink Partners Analyst forecast on IOVA
Asthika Goonewardene
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
02/25/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (NASDAQ: IOVA), Erasca (NASDAQ: ERAS) and Tempus AI, Inc. Class A (NASDAQ: TEM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
ONCBeOne Medicines
IRLAIRulya Therapeutics
IDYAIDEAYA Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Iovance Biotherapeutics

3 Months
Joseph PantginisH.C. Wainwright
Success Rate
14/15 ratings generated profit
93%
Average Return
+35.81%
Copying Joseph Pantginis's trades and holding each position for 3 Months would result in 93.33% of your transactions generating a profit, with an average return of +35.81% per trade.
1 Year
Etzer DaroutBarclays
Success Rate
13/13 ratings generated profit
100%
Average Return
+226.89%
Copying Etzer Darout's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +226.89% per trade.
2 Years
Joseph PantginisH.C. Wainwright
Success Rate
15/15 ratings generated profit
100%
Average Return
+454.64%
Copying Joseph Pantginis's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +454.64% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IOVA Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
11
9
7
3
2
Buy
1
1
4
11
13
Hold
0
0
2
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
10
13
16
18
In the current month, IOVA has received 15 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. IOVA average Analyst price target in the past 3 months is 14.40.
Each month's total comprises the sum of three months' worth of ratings.

IOVA Financial Forecast

IOVA Earnings Forecast

Next quarter’s earnings estimate for IOVA is -$0.09 with a range of -$0.10 to -$0.07. The previous quarter’s EPS was -$0.11. IOVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IOVA has Performed in-line its overall industry.
Next quarter’s earnings estimate for IOVA is -$0.09 with a range of -$0.10 to -$0.07. The previous quarter’s EPS was -$0.11. IOVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IOVA has Performed in-line its overall industry.

IOVA Sales Forecast

Next quarter’s sales forecast for IOVA is $115.53M with a range of $109.66M to $119.00M. The previous quarter’s sales results were $99.31M. IOVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IOVA has Performed in-line its overall industry.
Next quarter’s sales forecast for IOVA is $115.53M with a range of $109.66M to $119.00M. The previous quarter’s sales results were $99.31M. IOVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IOVA has Performed in-line its overall industry.

IOVA Stock Forecast FAQ

What is IOVA’s average 12-month price target, according to analysts?
Based on analyst ratings, Iovance Biotherapeutics Inc’s 12-month average price target is 14.40.
    What is IOVA’s upside potential, based on the analysts’ average price target?
    Iovance Biotherapeutics Inc has 70.62% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IOVA a Buy, Sell or Hold?
          Iovance Biotherapeutics Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Iovance Biotherapeutics Inc’s price target?
            The average price target for Iovance Biotherapeutics Inc is 14.40. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $20.00 ,the lowest forecast is $7.00. The average price target represents 70.62% Increase from the current price of $8.44.
              What do analysts say about Iovance Biotherapeutics Inc?
              Iovance Biotherapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of IOVA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.